Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study
Citations
1,214 citations
1,199 citations
1,056 citations
941 citations
735 citations
References
9,350 citations
4,423 citations
"Zoledronic acid reduces skeletal-re..." refers methods in this paper
...The questionnaire was part of a pain assessment tool, the Brief Pain Inventory.(18) Safety was monitored by reviewing adverse experiences, physical examinations, vital signs, and laboratory evaluations (hematology, blood chemistry, and urinalysis)....
[...]
...The questionnaire was part of a pain assessment tool, the Brief Pain Inventory.18 Safety was monitored by reviewing adverse experiences, physical examinations, vital signs, and laboratory evaluations (hematology, blood chemistry, and urinalysis)....
[...]
2,150 citations
1,024 citations
"Zoledronic acid reduces skeletal-re..." refers background or methods in this paper
...In two large prospective clinical trials, 33% of patients with metastatic breast carcinoma and 22% of patients with multiple myeloma who were receiving standard antineoplastic treatment required radiation therapy for bone metastases over 1-year and 9-month periods, respectively.(4,5) 1191...
[...]
...Pamidronate at a dose of 90 mg was superior to placebo in earlier Phase III trials evaluating its use in treatment of bone metastases in multiple myeloma and breast carcinoma patients.(4,5) In the current study, the proportions of patients treated with pamidronate or 2....
[...]
...tent data from three large protocols previously performed with pamidronate.(4,5,17) In those studies, patients with breast carcinoma and the subgroup of...
[...]
1,008 citations
"Zoledronic acid reduces skeletal-re..." refers background or methods in this paper
...In two large prospective clinical trials, 33% of patients with metastatic breast carcinoma and 22% of patients with multiple myeloma who were receiving standard antineoplastic treatment required radiation therapy for bone metastases over 1-year and 9-month periods, respectively.(4,5) 1191...
[...]
...Pamidronate at a dose of 90 mg was superior to placebo in earlier Phase III trials evaluating its use in treatment of bone metastases in multiple myeloma and breast carcinoma patients.(4,5) In the current study, the proportions of patients treated with pamidronate or 2....
[...]
...tent data from three large protocols previously performed with pamidronate.(4,5,17) In those studies, patients with breast carcinoma and the subgroup of...
[...]